162 related articles for article (PubMed ID: 36077097)
1. Treating iPSC-Derived β Cells with an Anti-CD30 Antibody-Drug Conjugate Eliminates the Risk of Teratoma Development upon Transplantation.
Pellegrini S; Zamarian V; Landi E; Cospito A; Lombardo MT; Manenti F; Citro A; Schiavo Lena M; Piemonti L; Sordi V
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077097
[TBL] [Abstract][Full Text] [Related]
2. Immunologic targeting of CD30 eliminates tumourigenic human pluripotent stem cells, allowing safer clinical application of hiPSC-based cell therapy.
Sougawa N; Miyagawa S; Fukushima S; Kawamura A; Yokoyama J; Ito E; Harada A; Okimoto K; Mochizuki-Oda N; Saito A; Sawa Y
Sci Rep; 2018 Feb; 8(1):3726. PubMed ID: 29487310
[TBL] [Abstract][Full Text] [Related]
3. Differentiation and transplantation of functional pancreatic beta cells generated from induced pluripotent stem cells derived from a type 1 diabetes mouse model.
Jeon K; Lim H; Kim JH; Thuan NV; Park SH; Lim YM; Choi HY; Lee ER; Kim JH; Lee MS; Cho SG
Stem Cells Dev; 2012 Sep; 21(14):2642-55. PubMed ID: 22512788
[TBL] [Abstract][Full Text] [Related]
4. Tumor-Free Transplantation of Patient-Derived Induced Pluripotent Stem Cell Progeny for Customized Islet Regeneration.
El Khatib MM; Ohmine S; Jacobus EJ; Tonne JM; Morsy SG; Holditch SJ; Schreiber CA; Uetsuka K; Fusaki N; Wigle DA; Terzic A; Kudva YC; Ikeda Y
Stem Cells Transl Med; 2016 May; 5(5):694-702. PubMed ID: 26987352
[TBL] [Abstract][Full Text] [Related]
5. Malignant germ cell-like tumors, expressing Ki-1 antigen (CD30), are revealed during in vivo differentiation of partially reprogrammed human-induced pluripotent stem cells.
Griscelli F; Féraud O; Oudrhiri N; Gobbo E; Casal I; Chomel JC; Biéche I; Duvillard P; Opolon P; Turhan AG; Bennaceur-Griscelli A
Am J Pathol; 2012 May; 180(5):2084-96. PubMed ID: 22425713
[TBL] [Abstract][Full Text] [Related]
6. Caffeic acid selectively eliminates teratogenic human-induced pluripotent stem cells via apoptotic cell death.
Kim A; Lee SY; Chung SK
Phytomedicine; 2022 Jul; 102():154144. PubMed ID: 35537368
[TBL] [Abstract][Full Text] [Related]
7. Ethanol extract of Magnoliae cortex (EEMC) limits teratoma formation of pluripotent stem cells by selective elimination of undifferentiated cells through the p53-dependent mitochondrial apoptotic pathway.
Kim A; Lee SY; Seo CS; Chung SK
Phytomedicine; 2020 Apr; 69():153198. PubMed ID: 32151917
[TBL] [Abstract][Full Text] [Related]
8. Generation of pancreatic insulin-producing cells from rhesus monkey induced pluripotent stem cells.
Zhu FF; Zhang PB; Zhang DH; Sui X; Yin M; Xiang TT; Shi Y; Ding MX; Deng H
Diabetologia; 2011 Sep; 54(9):2325-36. PubMed ID: 21755313
[TBL] [Abstract][Full Text] [Related]
9. In vivo surveillance and elimination of teratoma-forming human embryonic stem cells with monoclonal antibody 2448 targeting annexin A2.
Tan HL; Tan BZ; Goh WXT; Cua S; Choo A
Biotechnol Bioeng; 2019 Nov; 116(11):2996-3005. PubMed ID: 31388993
[TBL] [Abstract][Full Text] [Related]
10. Distinctive Clinical and Pathologic Features of Immature Teratomas Arising from Induced Pluripotent Stem Cell-Derived Beta Cell Injection in a Diabetes Patient.
Han L; He H; Yang Y; Meng Q; Ye F; Chen G; Zhang J
Stem Cells Dev; 2022 Mar; 31(5-6):97-101. PubMed ID: 35018826
[TBL] [Abstract][Full Text] [Related]
11. A novel enediyne-integrated antibody-drug conjugate shows promising antitumor efficacy against CD30
Wang R; Li L; Zhang S; Li Y; Wang X; Miao Q; Zhen Y
Mol Oncol; 2018 Mar; 12(3):339-355. PubMed ID: 29316337
[TBL] [Abstract][Full Text] [Related]
12. Preventing Pluripotent Cell Teratoma in Regenerative Medicine Applied to Hematology Disorders.
Bedel A; Beliveau F; Lamrissi-Garcia I; Rousseau B; Moranvillier I; Rucheton B; Guyonnet-Dupérat V; Cardinaud B; de Verneuil H; Moreau-Gaudry F; Dabernat S
Stem Cells Transl Med; 2017 Feb; 6(2):382-393. PubMed ID: 28191782
[TBL] [Abstract][Full Text] [Related]
13. Noninvasive detection of human-induced pluripotent stem cell (hiPSC)-derived teratoma with an integrin-targeting agent (99m)Tc-3PRGD2.
Li Y; Liu Z; Dong C; He P; Liu X; Zhu Z; Jia B; Li F; Wang F
Mol Imaging Biol; 2013 Feb; 15(1):58-67. PubMed ID: 22707047
[TBL] [Abstract][Full Text] [Related]
14. Fail-Safe System against Potential Tumorigenicity after Transplantation of iPSC Derivatives.
Itakura G; Kawabata S; Ando M; Nishiyama Y; Sugai K; Ozaki M; Iida T; Ookubo T; Kojima K; Kashiwagi R; Yasutake K; Nakauchi H; Miyoshi H; Nagoshi N; Kohyama J; Iwanami A; Matsumoto M; Nakamura M; Okano H
Stem Cell Reports; 2017 Mar; 8(3):673-684. PubMed ID: 28262544
[TBL] [Abstract][Full Text] [Related]
15. Prunellae Spica Extract Suppresses Teratoma Formation of Pluripotent Stem Cells through p53-Mediated Apoptosis.
Kim A; Lee SY; Seo CS; Chung SK
Nutrients; 2020 Mar; 12(3):. PubMed ID: 32182802
[TBL] [Abstract][Full Text] [Related]
16. Elimination of Teratogenic Human Induced Pluripotent Stem Cells by Bee Venom via Calcium-Calpain Pathway.
Kim A; Lee SY; Kim BY; Chung SK
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32380745
[TBL] [Abstract][Full Text] [Related]
17. The tumourigenicity of iPS cells and their differentiated derivates.
Liu Z; Tang Y; Lü S; Zhou J; Du Z; Duan C; Li Z; Wang C
J Cell Mol Med; 2013 Jun; 17(6):782-91. PubMed ID: 23711115
[TBL] [Abstract][Full Text] [Related]
18. Method for selective ablation of undifferentiated human pluripotent stem cell populations for cell-based therapies.
Chour T; Tian L; Lau E; Thomas D; Itzhaki I; Malak O; Zhang JZ; Qin X; Wardak M; Liu Y; Chandy M; Black KE; Lam MP; Neofytou E; Wu JC
JCI Insight; 2021 Apr; 6(7):. PubMed ID: 33830086
[TBL] [Abstract][Full Text] [Related]
19. Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis.
Blatt K; Cerny-Reiterer S; Schwaab J; Sotlar K; Eisenwort G; Stefanzl G; Hoermann G; Mayerhofer M; Schneeweiss M; Knapp S; Rülicke T; Hadzijusufovic E; Bauer K; Smiljkovic D; Willmann M; Reiter A; Horny HP; Valent P
Blood; 2015 Dec; 126(26):2832-41. PubMed ID: 26486787
[TBL] [Abstract][Full Text] [Related]
20. Direct
Xiang M; Lu M; Quan J; Xu M; Meng D; Cui A; Li N; Liu Y; Lu P; Kang X; Wang X; Sun N; Zhao M; Liang Q; Le L; Wang X; Zhang J; Chen S
Theranostics; 2019; 9(1):290-310. PubMed ID: 30662568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
